medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2012, Number 1

<< Back Next >>

Rev Med UV 2012; 12 (1)

Frequency of kidney damage and metabolic syndrome in patients with type 2 Diabetes mellitus and/or arterial hypertension in a primary care rural service in Mexico and evaluation of response to treatment

Acosta-Leyva JA, Ruiz-Ríos R, Preza-Martinez JA, Calderón-Garcidueñas AL

Language: Spanish
References: 20
Page: 14-19
PDF size: 358.45 Kb.


ABSTRACT

Chronic kidney disease (CKD) and metabolic syndrome (MS) contribute to mortality in patients with type 2 diabetes mellitus (T2DM) and systemic arterial hypertension (AH). Objective: Determine the frequency and stage of CKD and frequency of MS in patients with T2DM and / or hypertension and assess response to treatment. Methods: Observational, prospective and longitudinal study in a cohort of 63 patients with T2DM and / or AH in a rural area. Glomerular filtration was determined using the Cockcroft formula according to the NKF and MS diagnosed based on NCEP ATP III criteria. Patients were treated according to official standards for DM, AH, dyslipidemia (DL) and MS. We compared the metabolic control and renal function at 6 months of starting integral treatment. Results: 71.4 % had DM. 84.3% were females. 93.7% were in some stage of renal dysfunction. 30.2% were diagnosed with MS. The frequency of DL was 60.3%. We observed improvement with treatment in renal function in patients with stages II and III. Glycemic and arterial blood pressure control was also observed. Conclusions: The prevalence of CKD and MS is high in diabetic and hypertensive patients in a Mexican rural area. Most of the diabetic patients were in early stages of CKD. The detection of glomerular filtration by the Cockcroft formula and ATP III criteria allow identification and improvement of CKD. Integrated management of these patients improves renal function and metabolic syndrome and decreases the morbi-mortality.


REFERENCES

  1. Lavalle-González FJ, Chiquete E, de la Luz J, Ochoa-Guzmán A, Sánchez-Orozco LV, Godínez-Gutiérrez SA; the IDMPS-3W collaborative group (Mexico). Achievement of therapeutic targets in Mexican patients with diabetes mellitus. Endocrinol Nutr. 2012 Nov 5. pii: S1575-0922(12)00234-3. doi: 10.1016/j.endonu.2012.07.005.

  2. Hernandez-Rodriguez A, Rodriguez-Constantín A, Rodríguez-Beyris R. Enfermedad renal oculta en pacientes con diabetes mellitus. Medisan 2011; 15 (3): 293- 299.

  3. Murguía-Romero M, Jiménez-Flores R, Villalobos-Molina R, Méndez- Cruz AR. Estimating the geographical distribution of the prevalence of the metabolic syndrome in young Mexicans.Geospat Health. 2012;6(3):S43-S50.

  4. Debnath S, Thameem F, Alves T, Nolen J, Al-Shahrouri H, Bansal S, Abboud HE, Fanti P.Diabetic nephropathy among Mexican Americans.Clin Nephrol. 2012;77(4):332-44.

  5. Duran-Perez EG, Almeda-Valdes P, Cuevas-Ramos D, Campos-Barrera E, Muñoz-Hernandez L, Gomez-Perez FJ. Treatment of metabolic syndrome slows progression of diabetic nephropathy.Metab Syndr Relat Disord. 2011 Dec;9(6):483-9.

  6. Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.

  7. Hosseinpanah F, Borzooei S, Barzin M, Farshadi M, Sarvghadi F, Azizi F.Diagnostic Values of Metabolic Syndrome Definitions for Detection of Insulin Resistance: Tehran Lipid and Glucose Study (TLGS). Arch Iran Med. 2012 Oct;15(10):606-10.

  8. Cooper ME. Effect of losartan: renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J med 2001; 345: 861-9.

  9. Mendoza-Romo MA, Ramirez-Arriola MC. Consideraciones para calcular la depuración de creatinina con la fórmula de Cockcroft en pacientes con diabetes. Med Int Mex 2003; 19 (3): 161-4.

  10. Treviño-Becerra. ¿Por qué, cómo y para qué medir la filtracion glomerular?. Rev med Inst Mex Seguro Soc 2010; 48 (5): 465- 467.

  11. National Kydney Foundation. Normas de práctica clínica y las recomendaciones de práctica clínica para la diabetes y la insuficiencia renal crónica de la KDOQI de la fundación nacional del riñón. Am J Kidney Dis 2007; 49 (suppl 2): s1- s180.

  12. Norma Oficial Mexicana NOM-174-SSA1-1998, para el manejo integral de la obesidad.

  13. Cardona- Muñoz EG, Carranza- Madrigal J et al. Tratamiento. Modificaciones del estilo de vida. Tratamiento farmacológico. Actualización del Consenso Nacional de Hipertensión Arterial. Med Int Mex 2006; 22: 55- 63.

  14. Norma Oficial Mexicana NOM-030-SSA2-1999, para la prevencion, tratamiento y control de la hipertension arterial.

  15. Modificación a la Norma Oficial Mexicana NOM-015-SSA2-1994, para la prevencion, tratamiento y control de la diabetes mellitus.

  16. Norma Oficial Mexicana NOM-037-SSA2-2002, para la prevencion, tratamiento y control de las dislipidemias.

  17. Velazquez- López l, et al. Efecto de la dieta personalizada en el control metabólico y función renal de pacientes con diabetes tipo 2. Rev Med Inst Seguro Soc 2008; 46 (1): 11-18.

  18. Morales- Villegas EC, Et al. Manejo de las complicaciones crónicas de la diabetes mellitus. Complicaciones macrovasculares con foco en enfermedad coronaria aterosclerosa. Med int Mex 2010; 26 (5): 472-484.

  19. Campos-Mondragón MG, Et al. Síndrome metabólico y su correlación con los niveles séricos de urea, creatinina y ácido úrico en adultos de Veracruz. Rev Biomed 2010; 21 (2): 67- 75.

  20. Haller H, Ito S, Izzo JL, Et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364 (10): 907- 17.




2020     |     www.medigraphic.com